Efficacy and safety of insulin glargine/ lixisenatide fixed ratio combination compared to insulin glargine alone and lixisenatide alone on top of metformin in patients with T2DM

Registry ID

EUCTR2013-003131-30

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

sanofi-aventis recherche & développement

Start date

2014-01-10

Completion date

2015-06-17

Last update

2026-08-16

Conditions

• Type II Diabetes Mellitus

Summary

To compare the insulin glargine/lixisenatide fixed ratio combination to lixisenatide alone and to insulin glargine alone (on top of metformin treatment) in HbA1c change from baseline to week 30

Locations

• , , Italy
• , , Germany
• , , Belgium
• , , Estonia
• , , UK
• , , Sweden
• , , Lithuania
• , , Latvia
• , , Czechia
• , , Spain
• , , Hungary
• , , Denmark
• , , France

Related clinical trials

• The GRoceries Aimed at Increasing Nutrition Study
• A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
• cfMSC Therapy for Diabetes
• Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
• Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
• Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study

View on source registry